Home / Stocks / Granules India Limited
GRANULES

Granules India Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹801.2

Change

+3.7 (0.46%)

Open

₹792.0

Prev. Close

₹797.5

Day High

₹810.5

Day Low

₹788.45

Volume Analysis

Traded

1,128,414

Delivered

702,632

Delivery %

62.27%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (23.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹833.7 ₹822.1 ₹811.65 ₹800.05 ₹789.6 ₹778.0 ₹767.55
Fibonacci ₹822.1 ₹813.68 ₹808.47 ₹800.05 ₹791.63 ₹786.42 ₹778.0
Camarilla ₹807.26 ₹805.24 ₹803.22 ₹800.05 ₹799.18 ₹797.16 ₹795.14

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+29.39%

1 Week

-4.68%

1 Month

-0.8%

3 Months

-6.64%

6 Months

+6.55%

1 Year

+45.46%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹360.82

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

9.81%

Net margin 12.11% × asset turnover 0.6x × equity multiplier 1.35x

Company Overview

Sector

Healthcare

Market Cap

₹22,226 Cr

P/E (TTM)

31.7

ROE

13.8%

Book Value

₹241.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Granules India Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Growth (27/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (23.0%); promoter holding is falling. FII holding has been rising.

TopFund Score — Fundamentals Quality

65/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

27

Valuation

42

Cash Flow

50

Corporate Governance

50

Momentum

73

Institutional Ownership

78

Business Quality

74

Risk & Volatility

83

Liquidity

78

From Screener.in

  • +Company has reduced debt.
  • −Promoter holding has decreased over last quarter: -0.62%
  • −The company has delivered a poor sales growth of 10.6% over past five years.
  • −Company has a low return on equity of 13.7% over last 3 years.
  • −Dividend payout has been low at 7.84% of profits over last 3 years

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

KFin Technologies changes corporate office address effective December 1, 2026.

Transcript of the Earnings Conference Call for Q2 and the half year of FY27

Audio recording of Q2 and H1 FY27 earnings conference call uploaded.

Granules India filed Q2 FY27 monitoring report; no deviation in INR 1,762.50 crore preferential issue proceeds.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,189 1,156 1,176 1,180 967 1,138 1,197 1,210 1,297 1,388 1,471 1,477 1,560
Expenses + 977 905 920 921 763 907 945 963 1,019 1,080 1,119 1,138 1,222
Operating Profit 213 250 256 259 203 230 252 247 278 308 352 339 338
OPM % 18.0% 22.0% 22.0% 22.0% 21.0% 20.0% 21.0% 20.0% 21.0% 22.0% 24.0% 23.0% 22.0%
Other Income + 2 1 2 2 3 6 33 -10 -1 -4 25 2 11
Interest 26 29 29 27 26 27 24 24 29 29 33 21 21
Depreciation 53 52 53 53 53 57 64 69 72 74 82 80 84
Profit before tax 136 170 176 181 128 153 198 145 176 202 262 240 243
Tax % 25.0% 26.0% 26.0% 26.0% 24.0% 23.0% 23.0% 22.0% 26.0% 26.0% 23.0% 25.0% 25.0%
Net Profit + 102 126 130 135 97 118 152 113 131 150 202 180 182
EPS in Rs 4 5 5 6 4 5 6 5 5 6 8 7 7
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 3 1 -2 20 -19 -2 2 3 34 22 23 22 20

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,292 1,357 1,411 1,685 2,279 2,599 3,238 3,765 4,512 4,506 4,482 5,366 5,895
Expenses + 1,082 1,081 1,112 1,406 1,895 2,073 2,382 3,038 3,597 3,648 3,534 4,177 4,559
Operating Profit 210 276 299 278 384 526 856 727 915 858 948 1,188 1,337
OPM % 16.0% 20.0% 21.0% 17.0% 17.0% 20.0% 26.0% 19.0% 20.0% 19.0% 21.0% 22.0% 23.0%
Other Income + 3 5 35 27 75 90 26 13 12 2 41 7 34
Interest 32 37 32 33 28 27 26 23 56 106 103 114 103
Depreciation 53 58 72 76 105 137 151 159 184 207 226 296 319
Profit before tax 128 186 230 196 326 451 704 558 687 547 660 785 948
Tax % 29.0% 33.0% 28.0% 32.0% 27.0% 26.0% 22.0% 26.0% 25.0% 26.0% 24.0% 24.0% —
Net Profit + 91 123 165 133 236 335 549 413 517 405 502 595 714
EPS in Rs 4 6 7 5 9 13 22 17 21 17 21 24 28
Dividend Payout % 11.0% 11.0% 13.0% 19.0% 11.0% 8.0% 7.0% 9.0% 7.0% 9.0% 7.0% 7.0% —
Sales growth 19 5 4 19 35 14 25 16 20 0 -1 20 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 411 640 881 1,279 1,504 1,818 2,149 2,562 2,811 3,201 3,691 5,060 6,539
Borrowings + 482 641 656 978 991 892 849 1,106 1,136 1,315 1,455 1,512 1,101
Other Liabilities + 289 260 319 388 458 487 690 819 932 957 1,051 1,086 1,204
Total Liabilities 1,203 1,563 1,879 2,670 2,979 3,223 3,713 4,512 4,903 5,498 6,221 7,683 8,872
Fixed Assets + 617 560 644 777 944 1,204 1,332 1,541 1,911 2,096 2,426 3,250 3,605
CWIP 62 77 267 515 496 294 239 356 239 272 440 410 434
Investments 0 70 108 157 210 19 19 20 21 22 22 1 6
Other Assets + 524 856 859 1,222 1,328 1,706 2,123 2,594 2,732 3,109 3,333 4,022 4,827
Total Assets 1,203 1,563 1,879 2,670 2,979 3,223 3,713 4,512 4,903 5,498 6,221 7,683 8,872
Equity Capital 20 22 23 25 25 25 25 25 24 24 24 25 27

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 150 151 188 -1 262 476 432 332 739 439 867 793
Cash from Investing Activity + -146 -162 -326 -462 -270 -160 -277 -379 -192 -358 -689 -758
Cash from Financing Activity + 19 86 56 529 -17 -213 -299 190 -440 8 -93 379
Net Cash Flow 24 75 -82 66 -25 103 -144 143 107 90 85 414
Free Cash Flow 3 -10 -127 -447 -17 292 161 -65 328 61 297 239
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 87 72 83 21 91 113 73 66 100 73 107 87

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 41.97% → 37.39%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 29.1% 27.77% 26.61% 26.8% 25.71% 23.56% 24.41% 29.17% 30.15% 29.67% 28.36% 27.04%
Promoters 41.97% 41.96% 38.87% 38.87% 38.85% 38.83% 38.82% 38.81% 38.81% 38.02% 38.01% 37.39%
FII 18.78% 19.57% 20.39% 19.49% 15.87% 15.14% 13.24% 14.09% 13.55% 15.31% 17.5% 20.25%
DII 10.16% 10.7% 14.11% 14.85% 19.57% 22.45% 23.52% 17.91% 17.47% 17.01% 16.11% 15.33%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Granules India Limited (this stock) 22,226 31.7 3.39 13.8%
Alembic Pharma Ltd 20,652 23.0 3.48 13.4%
Onesource Specl Pharma L 18,464 1614.0 3.12 -1.09%
Eris Lifesciences Limited 18,448 24.7 4.45 18.7%
Syngene International Ltd 17,935 67.5 3.7 7.78%
Caplin Point Lab Ltd. 17,863 25.9 4.58 20.9%
Alivus Life Sciences Ltd 17,803 50.6 — —

Which Mutual Funds Hold Granules India Limited?

Frequently Asked Questions about Granules India Limited

Community Sentiment

What are other investors saying about Granules India Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.